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To quantify changes in anticoagulant use in Australia since the introduction of Non-vitamin
K antagonist anticoagulants (NOACs) and to estimate government expenditure.
Design
Interrupted-time-series analysis quantifying anticoagulant dispensing, before and after first
Pharmaceutical Benefits Scheme (PBS) NOAC listing in August 2009 for venous thrombo-
embolism prevention; and expanded listing for stroke prevention in non-valvular atrial fibrilla-
tion (AF) in August 2013, up to June 2016. Estimated government expenditure on PBS-
listed anticoagulants.
Setting and participants
PBS dispensing in 10% random sample of Australians, restricted to continuous conces-
sional beneficiaries dispensed oral anticoagulants from July 2005 to June 2016. Total PBS
anticoagulant expenditure was calculated using Medicare Australia statistics.
Main outcome measures
Monthly dispensing and initiation of oral anticoagulants (warfarin, rivaroxaban, dabigatran or
apixaban). Annual PBS anticoagulant expenditure.
Results
An estimated 149,180 concessional beneficiaries were dispensed anticoagulants (100%
warfarin) during July 2005. This increased to 292,550 during June 2016, of whom 47.0%,
27.1%, 18.7% and 7.2% were dispensed warfarin, rivaroxaban, apixaban and dabigatran,
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respectively. Of 16,500 initiated on anticoagulants in June 2016, 24.3%, 38.2%, 30.0% and
7.5% were initiated on warfarin, rivaroxaban, apixaban, and dabigatran, respectively. Com-
pared to July 2005-July 2013, from August 2013-June 2016, dispensings for all anticoagu-
lants increased by 2,303 dispensings/month (p<0.001, 95%CI = [1,229 3,376]); warfarin
dispensing decreased by 1,803 dispensings/month (p<0.001, 95%CI = [–2,606, –1,000]).
Total PBS anticoagulant expenditure was $19.5 million (97.0% concessional) in 2008/09, of
which 100% was warfarin and $203.3 million (86.2% concessional) in 2015/16, of which
11.2% was warfarin.
Conclusions
The introduction of the NOACs led to substantial increases in anticoagulant use and expen-
diture in Australia.
Introduction
Thrombotic disorders, including stroke and venous thromboembolism (VTE) contribute to
significant morbidity and mortality globally. Stroke is the second most common cause of
death, contributing to 10.1% of all deaths globally in 2016, and a major cause of disability
worldwide [1]. Atrial fibrillation (AF) is the most important cause of cardioembolic stroke, the
most severe subtype of ischaemic stroke, and is associated with an up to 5-fold increased risk
of stroke [2]. VTE, of which approximately one-third presents as pulmonary embolism and
the remainder as deep vein thrombosis, contributes to approximately 10% of all hospital
deaths, making it the single largest preventable cause of death in hospitalised patients [3].
Given the significant mortality and morbidity burden of stroke and VTE, effective prophylaxis
with oral anticoagulants (OACs), including warfarin, and the non-vitamin k oral anticoagu-
lants (NOACs) is essential.
Warfarin is the most extensively used OAC in the world, with 1-2% of adults in the devel-
oped world estimated to have been prescribed warfarin [4–7]. When used optimally, it is
highly efficacious, providing a relative risk reduction for stroke in patients with AF of 64%
compared to placebo [8]. However, warfarin requires complex management that is often com-
plicated because of its multiple interactions with foods and other medicines [9, 10]. Further-
more, there are significant risks with taking warfarin: up to 2% of people treated will
experience a major bleed, and between 0.1 and 0.5% will have an intracranial bleed [11–13].
There is extensive under-treatment of those at risk of stroke; at least one-third of patients
with AF and other known risk factors for stroke who are candidates for warfarin therapy do
not receive it [14]. NOACs–including rivaroxaban, dabigatran and apixaban–were listed on
the Australian Pharmaceutical Benefits Scheme (PBS) for prevention of VTE from August
2009 and for stroke prevention in AF from August 2013 to address this unmet need in antico-
agulant therapy. NOACs have many theoretical advantages over warfarin including compara-
ble or superior efficacy in trial populations (e.g. in AF, reduced risk of stroke,
thromboembolism, and all-cause mortality) and reduced monitoring requirements [15, 16].
However, NOACs are also considerably more costly than warfarin [17].
Despite their importance, evidence on the use of NOACs and their consideration as an
alternative to warfarin in the treatment of thrombotic conditions in Australia is limited. The
only previous relevant study, to our knowledge, examined the uptake of NOACs in the
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Australian Veterans’ population. It found rapidly increasing use of NOACs in this population
following their PBS listing for stroke prevention in AF and concluded that this may reflect use
in those previously contraindicated to warfarin [18]. However, the veterans’ population is very
elderly and has patterns of health services use that differ from the broader population, so evi-
dence on use in a more mainstream population is required.
The aim of this study is to quantify changes in OAC use in Australia using a representative
10% sample dataset of the PBS and to estimate total PBS OAC expenditure.
Methods
Context and setting
The PBS is Australia’s national medicine subsidy program, subsidising approximately 75% of
prescribed medicine use in Australia [19]. The PBS 10% sample used in this analysis is a stan-
dardised, longitudinal, unit-record extract containing all PBS medicine dispensing data for a
random 10% sample of Australians (approximately 2.5 million people) that is made available
for research purposes by the Department of Human Services [19].
All PBS medicines are assigned Anatomical Therapeutic Chemical (ATC) codes, as well as
unique PBS item codes that provide medicine details at the product level, including approved
indication, where applicable [19]. PBS item codes for NOACs (but not warfarin) provided a
proxy of the indication for use. Fig 1 provides an overview of the introduction of the NOACs
onto the Australian market for each of their approved indications for use.
Study population
To maintain consistency, the study population included continuous concessional beneficiaries
(individuals dispensed medicines attracting a concessional co-payment during the entire
study) dispensed anticoagulants. The PBS database does not capture data on medicines priced
lower than the patient co-payment until at least April 2012, and thereby under-ascertains the
utilisation of certain medicines prior to this time [19]. As the concessional co-payment thresh-
old is lower than the cost of nearly all medicines on the PBS, restricting to the concessional
population allows for more complete capture of medicine use over time.
At the beginning of the study period (during July 2005), 51.7% of the (14,918) dynamic
10% sample cohort dispensed OACs were male, 83.3% were aged 65 years and older, and 100%
were dispensed warfarin. At the end of the study period (during June 2016), 54.9% of the
(29,255) cohort were male, 90.2% were aged 65 years and older, and 46.0% were dispensed
warfarin. The dynamic nature of the study population did not allow for age-adjustment at a
population level.
Study variables
This analysis included all OAC (warfarin, rivaroxaban, dabigatran and apixaban) dispensing
records (for continuous concessional beneficiaries) during the study period of 1 July 2005 to
30 June 2016. OACs were identified by ATC code: warfarin (B01AA03); rivaroxaban
(B01AF01); dabigatran (B01AE07); and apixaban (B01AF02).
Statistical analysis
We calculated the number and proportion of Australian concessional beneficiaries dispensed
each OAC for each month of the study period using the PBS 10% sample and extrapolating the
findings to the overall PBS (continuous) long-term concessional population by multiplying the
population by ten-fold.
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The number and proportion of OAC users initiating a new course of each of the OACs
(‘initiators’), defined as individuals with no prior dispensings during the study period for at
least one year, including individuals with more than one year between dispensings of the same
or another anticoagulant, was also quantified. To compare changes in warfarin and total anti-
coagulant (warfarin and NOAC) dispensing following the introduction of the NOACs, an
interrupted time series analysis (ITSA) was performed using the Stata ‘ITSA’ command,
described elsewhere [20]. Two intervention periods were examined: the initial listing of the
first NOAC (rivaroxaban) in August 2009; and following the expanded indication for stroke
prevention in AF in August 2013 (for rivaroxaban; September 2013 for dabigatran and apixa-
ban) (Fig 2). The first intervention period (August 2009 to July 2013) was compared with the
pre-intervention period (July 2005 to July 2009), and the second intervention period (August
2013 to June 2016) was compared with the first intervention period (August 2009 to July
2013). The pre-intervention trend (slope) projected into the subsequent treatment period
serves as the counterfactual and is statistically compared to provide an estimate of the effect of
the interruption. Post-trend analysis estimates the post-intervention trends separately after the
first and second intervention periods.
Autocorrelation and seasonality between time points were tested and found to be present.
Seasonality was adjusted for using the Holt-Winters seasonal smoothing approach and the
Prais-Winsten ordinary least-squares regression approach (‘prais’ command in Stata) was used
to adjust for autocorrelation. Stata version 14.1 was used to perform all analyses.
PBS expenditure
Total PBS expenditure on anticoagulants was separately calculated using Medicare Australia
PBS item reports, which produce expenditure statistics based on requested PBS item codes
and by patient category (general or concessional) [21]. PBS expenditure is reported as expendi-
ture in the relevant year.
Fig 1. Timeline of NOAC market entry in Australia. Notes: The dates shown above the timeline are the PBS listing (reimbursement) dates while the dates shown
below the timeline are the Therapeutic Goods Administration (TGA) registration (market approval) dates for each of the approved indications for NOAC use. Legend:
Red: prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective total hip or total knee replacement surgery; Green: prevention
of stroke and systemic embolism in (adult) patients with non-valvular atrial fibrillation (AF) and at least one additional risk factor for stroke; Blue: Treatment (Tx) of
deep vein thrombosis (DVT) and pulmonary embolism (PE) and for the prevention (Pv) of recurrent DVT and PE in adults.
https://doi.org/10.1371/journal.pone.0208824.g001
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Results
Use
An estimated 149,180 concessional beneficiaries were dispensed OACs during July 2005, the
beginning of the study period, of whom 100% were dispensed warfarin. This increased to
292,550 in June 2016, of whom 47% were dispensed warfarin (Fig 2).
The proportion dispensed warfarin comprised more than 98% of concessional beneficiaries
dispensed OACs prior to August 2013. However, this decreased substantially in the first year
of the expanded NOAC listing from 95.2% (209,150/219,680) during August 2013 to 69.1%
(179,860/260,320) during July 2014.
Rivaroxaban dispensing increased from 1.7% (3,650/214,340) of those dispensed OACs
during July 2013 to 4.3% (9,540/219,680) during August 2013, and to 27.1% (79,130/292,550)
in June 2016. The proportion dispensed dabigatran was higher than those dispensed apixaban
until October 2014, when this observation was reversed. The proportion dispensed apixaban
continued to increase for the remainder of the study period to 18.7% (54,680/292,550), while
those dispensed dabigatran plateaued and were at 7.2% (21,120/292,550) in June 2016.
Rivaroxaban remained the most commonly dispensed NOAC throughout the study period
while warfarin remained the most commonly dispensed OAC overall, although use is declining
and the number of people dispensed NOACs exceeds warfarin. Dispensings for NOACs were
predominantly for use in stroke prevention in AF. From September 2013,<5% of monthly
NOAC dispensing was for prevention of VTE in patients undergoing hip or knee replacement.
Fig 2. Number of PBS concessional beneficiaries’ dispensed anticoagulants by month (July 2005–June 2016).
https://doi.org/10.1371/journal.pone.0208824.g002
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Initiation
The number of people initiating OACs per month during July 2006 was 3,710, all of whom
were initiated on warfarin. In June 2016, 16,500 people were initiated on OACs of whom
24.3% were initiated on warfarin (Fig 3).
The proportion of people initiating on warfarin decreased from 86.5% (6,700/7,750) in July
2013 to<50% (5,280/10,570) in September 2013, coinciding with the expanded PBS listing of
NOACs for stroke prevention in AF (August 2013).
At the end of the study period, rivaroxaban was the most commonly initiated OAC with
6,300 (38.2%) of the 16,500 people initiating OACs during the month of July 2016, followed by
4,960 (30.0%) with apixaban, 4,010 (24.3%) with warfarin and 1,230 (7.5%) with dabigatran.
Changes in OAC use
ITSA showed that from July 2005 to August 2009, the level and trend of OAC dispensing was
approximately 151,510 per month, increasing significantly by 692 dispensings per month
(p<0.001, 95% CI = [282, 1,103]) over this period (Fig 4). Following the initial introduction of
the NOACs on the PBS for VTE prophylaxis following major orthopaedic surgery (August
2009), no significant change in the level or trend of anticoagulant (or warfarin) dispensing was
seen. While this was not unexpected given that warfarin is available for a broader range of indi-
cations (such as coronary occlusion), it does provide a useful comparison of the more limited
use of NOACs in VTE prophylaxis compared with its expanded indication over time. Follow-
ing the second intervention period, which represents the expanded indication in stroke pre-
vention in AF (August 2013), dispensing of warfarin decreased significantly at a rate of 1,803
dispensings per month (p<0.001, 95% CI = [–2,606, –1,000]), while dispensing of OACs (war-
farin and NOACs) increased significantly at a rate of 2,303 dispensings per month (p<0.001,
95% CI = [1,229, 3,376]).
PBS expenditure
While the costs of PBS medicines can change over time depending on PBS policies, NOACs
are considerably more costly to the PBS than warfarin. At the end of the study period (June
2016), the dispensed price for warfarin was $15.38–$16.71 per pack, depending on the dosage
dispensed (1 mg–5mg, respectively). While the dispensed price for rivaroxaban was $37.59 –
$124.54, dabigatran was $36.19 –$109.12, and apixaban was $39.14 –$96.58, per pack depend-
ing on the dosage and quantity dispensed.
Annual PBS expenditure on OACs increased from $9.3 million (97.3% concessional) in
2005/06 to 19.5 million (97.0%) in 2008/09, of which 100% was on warfarin, to $203.3 million
(86.2% concessional) in 2015/16, of which 11.2% was warfarin, 47.4% rivaroxaban, 12.5% dabi-
gatran and 28.9% apixaban (Fig 5). PBS expenditure increased more than 8-fold from $25.1
million (94.3% concessional) in the year prior to the expanded NOAC indication (2012/13)
compared to $203.3 million (86.2% concessional) in 2015/16.
Discussion
The expanded listing of the NOACs onto the Australian PBS for stroke prevention in AF had a
rapid and substantial impact on OAC dispensing. We found that the gradually increasing use
of OACs more than tripled following the expanded NOAC listing, and increases in monthly
OAC dispensing far exceeded corresponding decreases in monthly dispensing of warfarin by
approximately 28%. Furthermore, three quarters of new use was in patients initiating on
NOAC, with the majority of patients initiating on rivaroxaban or apixaban at the end of the
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study period. Taken together, this indicates that, a substantial proportion of the increase was
attributed to additional patients being dispensed anticoagulants as opposed to switching from
warfarin to a NOAC. This finding likely reflects use in a subset of the population previously
unable to take warfarin, in addition to new patients being preferentially commenced on
NOACs.
Our findings of OAC use in a broader Australian population using a representative 10%
sample dataset corroborate international data demonstrating rapid adoption of NOACs in
clinical practice and rapid increases in anticoagulant expenditure and are consistent with a
previous Australian study in the Veterans’ population [22–24, 18].
PBS expenditure on anticoagulants increased more than 8-fold following the expanded PBS
listing of the NOACs from $25.1 million in 2012/13 to $203.3 million in 2015/16, consistent
with the changing pattern of NOACs observed in our analysis. However, the potential cost sav-
ings generated from reductions in health service use including laboratory monitoring and
MBS consultations that are likely associated with NOACs but not warfarin, are not reflected in
our expenditure estimates.
Nevertheless, it is important to consider whether the increased use of NOACs and associ-
ated expenditure that we have observed in practice is delivering value for money. While we
have not measured health benefits, we note that a recent Australian Government Review of
Anticoagulation Therapies in Atrial Fibrillation, recommended the restriction of NOACS to
use in people unable to tolerate warfarin to mitigate uncertainties regarding the magnitude of
any incremental clinical and cost-effectiveness benefit of NOACs over other therapies, and the
Fig 3. Number of people initiating anticoagulants by month.
https://doi.org/10.1371/journal.pone.0208824.g003
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total high unpredicted cost [25]. Neither Australian clinical guidelines, PBS listings nor, as
shown by our findings, clinical practice presently adopted these recommendations. However,
this is important to consider in the context of the potential for savings in terms of reductions
in health service usage from preventing strokes given their significant burden.
The main strengths of this study are its large, representative sample and detailed indepen-
dent administrative information on medicine dispensing in the Australian population. We
used an ITSA design to assess statistically the impact that the NOACs had on the level and
trend of anticoagulant dispensing in the PBS concessional population using the PBS 10%
sample.
To maintain consistency in the population over time, the study was restricted to conces-
sional beneficiaries only and excluded general beneficiaries and anyone with a change in con-
cessional status over the study period thereby potentially substantially underestimating
dispensing trends. However, as most people aged 65 years and older are concessional, they also
represent the primary users of OACs. While the PBS 10% sample provides useful information
Fig 4. Interrupted time series analysis of warfarin and all anticoagulant dispensings.
https://doi.org/10.1371/journal.pone.0208824.g004
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about dispensing in the Australian population, it does not provide clinical information on
medicine use, therefore no conclusions can be made about the intended (e.g. fewer strokes)
and unintended (e.g. increased bleeds) outcomes of anticoagulant use.
The expanded PBS listing of the NOACs for stroke prevention in AF rapidly accelerated
steadily increasing use of PBS anticoagulant dispensing and expenditure. At least some of
these changes may reflect use in Australians previously unwilling or unable to take warfarin,
increasing the overall anticoagulant-treated population. However, this needs to be considered
in the context of the substantial economic impact that the listing of the NOACs has had on
PBS anticoagulant expenditure. Post-market experience with NOACs, including analyses of
administrative data, has the potential to help inform ongoing cost-effective use of NOACs.
With further market experience and post-market safety and efficacy surveillance, we may be
able to evaluate whether this investment has contributed to lessening the burden of stroke and
VTE in Australia.
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Fig 5. PBS expenditure on anticoagulants (2005/06–2015/16).
https://doi.org/10.1371/journal.pone.0208824.g005
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